Non-alcoholic Steatohepatitis 2017 Global Market Expected to Grow at CAGR 24.58% and Forecast to 2021

“\”Non-alcoholic Steatohepatitis Market\””
The analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.


Global Non-alcoholic Steatohepatitis Market


WiseGuyReports.Com adds” Global Non-alcoholic Steatohepatitis Market 2016-2020 “Research To Its Database.

NAFL disease, also known as fatty infiltration, is characterized by the accumulation of fat in the liver. It is of two types: NAFL and NASH. Fatty inflammation characterized by higher fat deposition than the normal level, 5%-10%, causes the disease. NASH causes severe inflammation of the liver, leading to damage of the organ. It is a benign condition of unknown etiology and is asymptomatic in nature during its initial stages, resulting in late diagnosis. Conditions such as obesity, diabetes, hyperlipidemia, insulin resistance, and toxicity by drugs such as amiodarone, tamoxifen, and perhexiline maleate can cause NASH. 

The analysts forecast the global NASH market to grow at a CAGR of 24.58% during the period 2016-2020.

Covered in this report 
The report covers the present scenario and the growth prospects of the global NASH market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of off-label drugs, originally indicated for the treatment of diabetes, obesity, and associated conditions.


Get sample Report @


The market is divided into the following segments based on geography
• Americas 

The Global NASH Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors 
• Arena Pharmaceuticals 
• AstraZeneca 
• F Hoffmann-La Roche 
• GSK 
• Novo Nordisk 
• Vivus

Other prominent vendors 
• Arisaph Pharmaceuticals 
• Cempra Pharmaceuticals 
• Galectin Therapeutics 
• Galmed Pharmaceuticals 
• Genfit 
• Gilead 
• Immuron 
• Interceptpharma 
• Raptor Pharmaceutical 
• Shire 
• Tobira Therapeutics 
• Verva 
• Viking Therapeutics

Market driver 
• Increase in sedentary lifestyle 
• For a full, detailed list, view our report

Market challenge 
• Limited understanding of disease pathophysiology 
• For a full, detailed list, view our report

Market trend 
• Patient assistance programs 
• For a full, detailed list, view our report

Key questions answered in this report 
• What will the market size be in 2020 and what will the growth rate be? 
• What are the key market trends? 
• What is driving this market? 
• What are the challenges to market growth? 
• Who are the key vendors in this market space? 
• What are the market opportunities and threats faced by the key vendors? 
• What are the strengths and weaknesses of the key vendors?


Enquiry About Report @


Table of Contents -Major Key Points

PART 01: Executive summary 
• Highlights 

PART 02: Scope of the report 
• Market overview 
• Top-vendor offerings 

PART 03: Market research methodology 
• Research methodology 
• Economic indicators 

PART 04: Introduction 
• Key market highlights 

PART 05: Disease overview 
• Understanding the disease 
• Symptoms and signs 
• Pathophysiology 
• Risk factors 
• Diagnosis 
• Treatment 
• Epidemiology 
• Economic burden 

PART 06: Pipeline analysis 
• Pipeline information of NASH 
• Clinical trials for NASH 

PART 07: Market landscape 
• Market overview 
• Market size and forecast 
• Five forces analysis 

PART 08: Market segmentation by dosage form 
• Solid 
• Liquid 

PART 09: Market segmentation by route of administration 
• Oral 
• Parenteral 

PART 10: Geographical segmentation 
• Global NASH drugs market by geographical segmentation 2015-2020 
• NASH drugs market in Americas 
• NASH drugs market in US 
• NASH drugs market in EMEA 
• NASH drugs market in APAC 

PART 11: Market drivers 
• Increase in sedentary lifestyle 
• Prevalence of associated health conditions 
• Promising pipeline 
• Significant unmet medical needs 

PART 12: Impact of drivers 

PART 13: Market challenges 
• Limited understanding of disease pathophysiology 
• Insufficient diagnostic technology for NASH 
• Stringent regulatory procedure 
• Adverse effects of drugs 

PART 14: Impact of drivers and challenges 

PART 15: Market trends 
• Rise in public awareness 
• Increase in strategic alliances 
• Patient assistance programs 
• Usage of off-label drugs 



Media Contact
Company Name:
Contact Person: Norah Trent
Phone: +1 646 845 9349, +44 208 133 9349
City: Pune
State: Maharashtra
Country: India